AbbVie and Enigma Biomedical Group (EBG-USA) Enter into a Licensing Agreement to Develop and Commercialize 4R Tau PET Imaging Biomarkers
Shots:
- Abbvie and EBG-USA have entered into an exclusive license and option agreement to develop and commercialize the former’s F18 PET imaging biomarkers for identifying 4R tau protein in suspected neurodegenerative disease patients
- Under the agreement, both of them will work with EBG-USA's academic and pharmaceutical partners to assess F18 PET imaging biomarkers, initially, for validating preclinical and clinical PET ligands & if validated, EBG-USA holds the option to negotiate an exclusive license agreement with AbbVie for the PET ligands
- The 4R tau PET imaging biomarkers have the potential to understand the neurodegenerative diseases associated with progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD)
Ref: Businesswire | Image: AbbVie
Related News:- ConcertAI, Caris Life Sciences, and AbbVie Collaborate to Enhance AbbVie’s Research and Development Efforts Towards Cancer Treatment
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Shivani is a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
